Evelyn Partners Investment Management LLP
Position in APLS — Apellis Pharmaceuticals, Inc.
CIK 2065206
London, X0
Position in APLS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
150
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Evelyn Partners Investment Management LLP holds $149,476 across 6 Biotechnology names. APLS ranks #6 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRSP |
CRISPR Therapeutics AG
|
1,300 | $61,841 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
175 | $57,902 | |
| 3 | ARVN |
Arvinas, Inc.
|
1,474 | $15,624 | |
| 4 | ONC |
BeOne Medicines Ltd.
|
41 | $12,175 | |
| 5 | PRTA |
Prothena Corp Public Ltd Co
|
199 | $1,934 | |
| 6 | APLS |
Apellis Pharmaceuticals, Inc.
This page
|
150 | $0 |
All Filings in APLS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 150 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | — | 150 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | — | 150 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | — | 150 | Shares | Sole | 2025-11-26 | |
| 2025-03-31 | — | 150 | Shares | Sole | 2025-12-08 | |
| 2024-12-31 | — | 150 | Shares | Sole | 2025-12-11 | |
| No filing history on record for this holder in this stock. | ||||||